Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by DEBORAH A KUBAN and KAREN HOFFMAN.
DEBORAH A KUBAN
Connection Strength
5.328
KAREN HOFFMAN
  1. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol. 2018 10 10; 36(29):2943-2949.
    View in: PubMed
    Score: 0.666
  2. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. Am J Clin Oncol. 2018 Jun; 41(6):558-567.
    View in: PubMed
    Score: 0.657
  3. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1074-84.
    View in: PubMed
    Score: 0.492
  4. Lymph node-positive prostate cancer: the benefit of local therapy. Oncology (Williston Park). 2013 Jul; 27(7):655, 660-1.
    View in: PubMed
    Score: 0.467
  5. Implementation and Efficacy of a Large-Scale Radiation Oncology Case-Based Peer-Review Quality Program across a Multinational Cancer Network. Pract Radiat Oncol. 2024 Jan 03.
    View in: PubMed
    Score: 0.242
  6. Patients' Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer. MDM Policy Pract. 2022 Jul-Dec; 7(2):23814683221137752.
    View in: PubMed
    Score: 0.224
  7. Reply to Multidisciplinary clinics: A possible means to help to eliminate racial disparities in prostate cancer. Cancer. 2020 06 15; 126(12):2939-2940.
    View in: PubMed
    Score: 0.186
  8. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514.
    View in: PubMed
    Score: 0.182
  9. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548.
    View in: PubMed
    Score: 0.157
  10. Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):249-258.
    View in: PubMed
    Score: 0.155
  11. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. 2016 08; 39(4):368-73.
    View in: PubMed
    Score: 0.145
  12. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med. 2014 Sep; 174(9):1450-9.
    View in: PubMed
    Score: 0.127
  13. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw. 2014 Jul; 12(7):993-8.
    View in: PubMed
    Score: 0.125
  14. Current clinical presentation and treatment of localized prostate cancer in the United States. J Urol. 2014 Dec; 192(6):1650-6.
    View in: PubMed
    Score: 0.125
  15. Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e239-46.
    View in: PubMed
    Score: 0.123
  16. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. 2013 Sep 15; 119(18):3265-71.
    View in: PubMed
    Score: 0.117
  17. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer. 2013 Aug 01; 119(15):2771-7.
    View in: PubMed
    Score: 0.115
  18. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46.
    View in: PubMed
    Score: 0.111
  19. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):693-9.
    View in: PubMed
    Score: 0.109
  20. Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer. 2012 Jul; 48(11):1664-71.
    View in: PubMed
    Score: 0.106
  21. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J. 2012 Jan-Feb; 18(1):1-8.
    View in: PubMed
    Score: 0.105
  22. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011 Jan; 185(1):116-20.
    View in: PubMed
    Score: 0.097
  23. Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy. 2020 Sep - Oct; 19(5):574-583.
    View in: PubMed
    Score: 0.048
  24. Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):982-985.
    View in: PubMed
    Score: 0.047
  25. Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol. 2020 Jul - Aug; 10(4):282-292.
    View in: PubMed
    Score: 0.047
  26. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open. 2020 03 02; 3(3):e201255.
    View in: PubMed
    Score: 0.046
  27. Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. 2019 11; 124(5):811-819.
    View in: PubMed
    Score: 0.044
  28. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):790-797.
    View in: PubMed
    Score: 0.043
  29. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):374-382.
    View in: PubMed
    Score: 0.039
  30. Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial. Int J Part Ther. 2016; 3(1):27-36.
    View in: PubMed
    Score: 0.036
  31. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
    View in: PubMed
    Score: 0.034
  32. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):946-53.
    View in: PubMed
    Score: 0.030
  33. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. 2014 Mar-Apr; 13(2):157-62.
    View in: PubMed
    Score: 0.030
  34. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy. 2013 May-Jun; 12(3):204-9.
    View in: PubMed
    Score: 0.027
  35. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):e7-e13.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.